Joby Aviation closes $591 million stock offering with full underwriter option
DANBURY/BURLINGTON - MannKind Corporation (NASDAQ:MNKD) announced Monday it will acquire scPharmaceuticals Inc. (NASDAQ:SCPH) in a deal valued at up to $360 million, expanding its portfolio into cardiorenal medicine. The acquisition target, currently valued at $260.1 million, has shown impressive momentum with a 46% price return over the past six months, according to InvestingPro data.
Under the agreement, MannKind will pay $5.35 per share in cash upfront, representing a 36% premium to scPharmaceuticals’ 90-day volume-weighted average price. Shareholders will also receive one non-tradable contingent value right worth up to an additional $1.00 per share upon achieving specific regulatory and sales milestones.
The acquisition adds FUROSCIX to MannKind’s product lineup. FUROSCIX is an FDA-approved on-body infuser delivering furosemide for treating fluid overload in adult patients with chronic heart failure and chronic kidney disease.
scPharmaceuticals reported $27.8 million in net sales for the first half of 2025, a 96% increase year-over-year. This growth aligns with the company’s strong financial metrics, including a robust gross profit margin of 68.5% and healthy liquidity position with a current ratio of 3.85, as revealed by InvestingPro analysis. The company is preparing a supplemental New Drug Application for its FUROSCIX ReadyFlow Autoinjector in the third quarter of 2025, which could potentially reduce treatment time from five hours to less than 10 seconds.
"This acquisition expands our patient-centered brands and highlights MannKind’s dedication to delivering innovative therapies for cardiometabolic and orphan lung diseases," said Michael Castagna, CEO of MannKind Corporation, in the press release statement.
The transaction, expected to close in the fourth quarter of 2025, will be funded partly through a $175 million strategic financing agreement with Blackstone. Upon closing, MannKind will repay scPharmaceuticals’ outstanding debt to Perceptive, estimated at $81 million.
The combined company is projected to have an annualized revenue run rate exceeding $370 million based on second-quarter 2025 results, according to the announcement.
The deal remains subject to regulatory approvals and other customary closing conditions.
In other recent news, SC Pharmaceuticals reported its Q2 2025 earnings, revealing a mixed financial performance. The company achieved net revenue of $16 million, which exceeded forecasts and represented a 99% increase compared to the previous year. However, the earnings per share (EPS) were -$0.34, falling short of the expected -$0.29. Additionally, SC Pharmaceuticals announced an amendment to its supply agreement with West Pharmaceutical Services. This amendment, effective August 20, 2025, extends the term of the supply arrangement through December 31, 2027. The agreement outlines that if either party decides to terminate, SC Pharmaceuticals will be responsible for any costs incurred and purchase orders accepted up to the termination date. These developments reflect the company’s ongoing efforts to manage its supply chain and financial outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.